ECSP22022403A - Proceso industrial para la preparación de estetrol de alta pureza - Google Patents
Proceso industrial para la preparación de estetrol de alta purezaInfo
- Publication number
- ECSP22022403A ECSP22022403A ECSENADI202222403A ECDI202222403A ECSP22022403A EC SP22022403 A ECSP22022403 A EC SP22022403A EC SENADI202222403 A ECSENADI202222403 A EC SENADI202222403A EC DI202222403 A ECDI202222403 A EC DI202222403A EC SP22022403 A ECSP22022403 A EC SP22022403A
- Authority
- EC
- Ecuador
- Prior art keywords
- estetrol
- preparation
- high purity
- industrial process
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0074—Esters
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere a la preparación de estetrol de fórmula (I), derivados del mismo protegido en las posiciones 3,15α,16α,17β de fórmula general (III), y derivados 3-hidroxi del mismo protegido en las posiciones 15α,16α,17β de fórmula general (IV), y a los productos intermedios de fórmulas generales (III) y (IV) aplicados en el proceso. Otro aspecto de la invención es la aplicación de estetrol de fórmula (I) obtenido por el proceso de la invención para la preparación de una composición farmacéutica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1900315A HU231240B1 (hu) | 2019-09-03 | 2019-09-03 | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
| PCT/IB2020/058148 WO2021044302A1 (en) | 2019-09-03 | 2020-09-02 | Industrial process for the preparation of high purity estetrol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22022403A true ECSP22022403A (es) | 2022-04-29 |
Family
ID=89992977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202222403A ECSP22022403A (es) | 2019-09-03 | 2022-03-24 | Proceso industrial para la preparación de estetrol de alta pureza |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US11633406B2 (es) |
| EP (1) | EP3877395B1 (es) |
| JP (1) | JP7265087B2 (es) |
| KR (1) | KR102871606B1 (es) |
| CN (1) | CN114302889B (es) |
| AU (1) | AU2020343497B2 (es) |
| CA (1) | CA3147815C (es) |
| CL (1) | CL2022000492A1 (es) |
| CO (1) | CO2022003769A2 (es) |
| CU (1) | CU24692B1 (es) |
| DK (1) | DK3877395T3 (es) |
| EC (1) | ECSP22022403A (es) |
| ES (1) | ES2855923T3 (es) |
| FI (1) | FI3877395T3 (es) |
| GE (1) | GEP20247626B (es) |
| HR (1) | HRP20230230T1 (es) |
| HU (2) | HU231240B1 (es) |
| IL (1) | IL290973B2 (es) |
| JO (1) | JOP20220041A1 (es) |
| LT (1) | LT3877395T (es) |
| MA (1) | MA54200B1 (es) |
| MD (1) | MD3877395T2 (es) |
| MX (1) | MX2022002603A (es) |
| MY (1) | MY206905A (es) |
| NZ (1) | NZ786568A (es) |
| PE (1) | PE20221418A1 (es) |
| PH (1) | PH12022550388A1 (es) |
| PL (1) | PL3877395T3 (es) |
| PT (1) | PT3877395T (es) |
| RS (1) | RS63966B1 (es) |
| SI (1) | SI3877395T1 (es) |
| WO (1) | WO2021044302A1 (es) |
| ZA (1) | ZA202203557B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022005359A2 (pt) * | 2019-09-27 | 2022-07-19 | Ind Chimica Srl | Processo de preparação de (15a,16a,17ss)-estra-1,3,5(10)-trieno-3,15,16,17-tetrol(estetrol) e intermediários do referido processo |
| DE112021008305T5 (de) * | 2021-10-01 | 2024-07-25 | Industriale Chimica S.R.L. | VERFAHREN ZUR HERSTELLUNG VON (15α,16α,17β)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-TETROL (ESTETROL) UND ESTETROL-MONOHYDRAT |
| HUP2500316A1 (en) * | 2023-02-02 | 2025-11-28 | Ind Chimica Srl | Process for preparing (15alpha,16alpha,17beta)-estra-1,3,5(10)-triene-3,15,16,17-tetrol (estetrol) monohydrate |
| CN117088928B (zh) * | 2023-08-16 | 2025-09-09 | 湖北共同甾体药物研究院有限公司 | 用于制备高纯度雌四醇的工艺 |
| CN119569803B (zh) * | 2023-09-05 | 2025-09-16 | 秦皇岛紫竹药业有限公司 | 一种制备高纯度雌四醇的方法 |
| HUP2400151A1 (hu) | 2024-02-28 | 2025-09-28 | Richter Gedeon Nyrt | Ösztetrol-monohidrát kristályosítási eljárás |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE350041T1 (de) | 2001-05-18 | 2007-01-15 | Pantarhei Bioscience Bv | Pharmaceutishe zusammensetzung für die hormonersatztherapie |
| EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
| EP1390042B1 (en) | 2001-05-23 | 2007-11-28 | Pantarhei Bioscience B.V. | Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
| WO2002094278A1 (en) | 2001-05-23 | 2002-11-28 | Pantarhei Bioscience B.V. | Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
| ATE347365T1 (de) | 2001-11-15 | 2006-12-15 | Pantarhei Bioscience Bv | Verwendung von öestrogen in kombination mit progestogen für die hormonsubstitutions-therapie |
| DE60308679T2 (de) | 2002-06-11 | 2007-08-16 | Pantarhei Bioscience B.V. | Methode zur behandlung oder prävention immunologischer erkrankungen und pharmazeutische zusammensetzung zur solchen anwendung |
| EP1511498B1 (en) | 2002-06-11 | 2012-11-21 | Pantarhei Bioscience B.V. | A method of treating human skin and a skin care composition for use in such a method |
| EP1526856B1 (en) | 2002-07-12 | 2008-01-02 | Pantarhei Bioscience B.V. | Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy |
| US8987240B2 (en) | 2002-10-23 | 2015-03-24 | Pantarhei Bioscience B.V. | Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy |
| AU2003279624A1 (en) * | 2002-11-08 | 2004-06-07 | Pantarhei Bioscience B.V. | Synthesis of estetrol via estrone derived steroids |
| WO2007081206A1 (en) | 2006-01-09 | 2007-07-19 | Pantarhei Bioscience B.V. | A method of treating an acute vascular disorder |
| DE602008001783D1 (de) | 2007-01-08 | 2010-08-26 | Pantarhei Bioscience Bv | Verfahren zur behandlung oder prävention von unfruchtbarkeit bei weiblichen säugern und pharmazeutisches kit zur anwendung dieses verfahrens |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| ES2631359T3 (es) | 2011-08-11 | 2017-08-30 | Estetra S.P.R.L. | Uso del estetrol como anticonceptivo de emergencia |
| HRP20161282T1 (hr) | 2011-10-07 | 2016-11-18 | Estetra S.P.R.L. | Postupak za proizvodnju estetrola |
| EP2653163A1 (en) | 2012-04-19 | 2013-10-23 | Université de Liège | Estrogenic components for use in the treatment of neurological disorders |
| WO2013034780A2 (en) | 2012-12-20 | 2013-03-14 | Crystal Pharma, S.A.U. | Process for the preparation of estetrol and related compounds |
| US9988417B2 (en) * | 2013-09-18 | 2018-06-05 | Crystal Pharma, S.A.U. | Process for the preparation of estetrol |
| JP6447931B2 (ja) | 2013-12-12 | 2019-01-09 | ドネスタ バイオサイエンス ビー．ブイ．Ｄｏｎｅｓｔａ Ｂｉｏｓｃｉｅｎｃｅ Ｂ．Ｖ． | エステトロール成分を含有する口腔内崩壊固体単位剤形 |
| JP6813150B2 (ja) | 2015-06-18 | 2021-01-13 | エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ | エステトロールを含有する口腔内崩壊錠 |
| PL3310345T3 (pl) | 2015-06-18 | 2021-10-18 | Estetra Sprl | Ulegająca rozpadowi w jamie ustnej tabletka zawierająca estetrol |
| LT3701944T (lt) | 2015-06-18 | 2022-04-11 | Estetra Srl | Burnoje disperguojamas dozavimo vienetas, kurio sudėtyje yra estetrolio komponentas |
| KR102712911B1 (ko) | 2016-08-05 | 2024-10-04 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
| JP2018533542A (ja) | 2016-10-28 | 2018-11-15 | エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ | 月経困難症および月経痛の管理のための方法 |
| ES2906380T3 (es) | 2017-08-01 | 2022-04-18 | Fund Sa | Terapia adyuvante para usar en el tratamiento del cáncer de próstata |
| CA3178181A1 (en) | 2018-02-07 | 2019-08-15 | Estetra Srl | Contraceptive composition with reduced cardiovascular effects |
| BR112022005359A2 (pt) * | 2019-09-27 | 2022-07-19 | Ind Chimica Srl | Processo de preparação de (15a,16a,17ss)-estra-1,3,5(10)-trieno-3,15,16,17-tetrol(estetrol) e intermediários do referido processo |
-
2019
- 2019-09-03 HU HU1900315A patent/HU231240B1/hu unknown
-
2020
- 2020-09-02 DK DK20768398.8T patent/DK3877395T3/da active
- 2020-09-02 CU CU2022000013A patent/CU24692B1/es unknown
- 2020-09-02 GE GEAP202015920A patent/GEP20247626B/en unknown
- 2020-09-02 CN CN202080061521.1A patent/CN114302889B/zh active Active
- 2020-09-02 JO JOP/2022/0041A patent/JOP20220041A1/ar unknown
- 2020-09-02 PL PL20768398.8T patent/PL3877395T3/pl unknown
- 2020-09-02 CA CA3147815A patent/CA3147815C/en active Active
- 2020-09-02 MX MX2022002603A patent/MX2022002603A/es unknown
- 2020-09-02 JP JP2022511285A patent/JP7265087B2/ja active Active
- 2020-09-02 US US17/639,206 patent/US11633406B2/en active Active
- 2020-09-02 AU AU2020343497A patent/AU2020343497B2/en active Active
- 2020-09-02 PT PT207683988T patent/PT3877395T/pt unknown
- 2020-09-02 KR KR1020227010919A patent/KR102871606B1/ko active Active
- 2020-09-02 SI SI202030156T patent/SI3877395T1/sl unknown
- 2020-09-02 NZ NZ786568A patent/NZ786568A/en unknown
- 2020-09-02 HU HUE20768398A patent/HUE061427T2/hu unknown
- 2020-09-02 MY MYPI2022000866A patent/MY206905A/en unknown
- 2020-09-02 EP EP20768398.8A patent/EP3877395B1/en active Active
- 2020-09-02 IL IL290973A patent/IL290973B2/en unknown
- 2020-09-02 HR HRP20230230TT patent/HRP20230230T1/hr unknown
- 2020-09-02 LT LTEPPCT/IB2020/058148T patent/LT3877395T/lt unknown
- 2020-09-02 FI FIEP20768398.8T patent/FI3877395T3/fi active
- 2020-09-02 PE PE2022000348A patent/PE20221418A1/es unknown
- 2020-09-02 RS RS20230112A patent/RS63966B1/sr unknown
- 2020-09-02 MA MA54200A patent/MA54200B1/fr unknown
- 2020-09-02 ES ES20768398T patent/ES2855923T3/es active Active
- 2020-09-02 MD MDE20210894T patent/MD3877395T2/ro unknown
- 2020-09-02 WO PCT/IB2020/058148 patent/WO2021044302A1/en not_active Ceased
-
2022
- 2022-02-28 CL CL2022000492A patent/CL2022000492A1/es unknown
- 2022-03-24 EC ECSENADI202222403A patent/ECSP22022403A/es unknown
- 2022-03-28 ZA ZA2022/03557A patent/ZA202203557B/en unknown
- 2022-03-29 CO CONC2022/0003769A patent/CO2022003769A2/es unknown
- 2022-09-02 PH PH1/2022/550388A patent/PH12022550388A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP22022403A (es) | Proceso industrial para la preparación de estetrol de alta pureza | |
| CL2020002695A1 (es) | Péptidos macrocíclicos contra actinetobacter baumannii | |
| CL2019003281A1 (es) | Derivados de piperidina. (divisional solicitud 201900169) | |
| CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
| BR112015012425A2 (pt) | composto, composição farmacêutica, método e medicamento para o tratamento de doenças medicadas pela proteína parp-1 e uso do composto | |
| CO2020011852A2 (es) | Inhibidores de canales receptores de potencial transitorio de oxadiazol | |
| CO2020007018A2 (es) | Proceso para preparar tapinarof | |
| AR094876A1 (es) | Derivados de ácido betulínico modificados con alquilo c-3 y alquenilo | |
| CR20180232A (es) | Macrociclos peptídicos contra acinetobacter baumannii | |
| AR081638A1 (es) | Amidas c-28 de derivados del acido betulinico c-3 modificados como inhibidores de la maduracion del vih | |
| CO6670589A2 (es) | Compuestos para reducir la producción de beta-amiloide | |
| CL2023002322A1 (es) | Derivados de hidroxiheterocicloalquil-carbamoilo | |
| AR086987A1 (es) | 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia | |
| MX2022002941A (es) | Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo. | |
| MX2024015537A (es) | Peptidos ciclicos para atrapar interleucina-1 beta | |
| DOP2024000239A (es) | Compuestos amido heteroaromáticos útiles en el tratamiento de enfermedades hepáticas | |
| AR127431A1 (es) | Compuestos novedosos | |
| CU20200100A7 (es) | Compuestos 3-ciano n-sustituidos de hidrotienopiridina útiles para prevenir y tratar las infecciones virales, especialmente dengue, y composiciones farmacéuticas que los contienen | |
| CL2018002095A1 (es) | Un derivado de piridina representado por las formulas i a iii y una sal farmacéuticamente aceptable del mismo; procedimiento de preparación del derivado de piridina o la sal farmacéuticamente aceptable del mismo; composición farmacéutica y su uso para preparar un medicamento útil para la prevención o tratamiento de una enfermedad de crecimiento celular anómalo producida por una mutación ras. | |
| MX2023004955A (es) | Compuestos de aminotiazol deuterados como compuestos antiviricos. | |
| MX2025006719A (es) | Análogos de nucleótidos, composiciones y usos de los mismos | |
| CL2024001852A1 (es) | Sal derivada de triazolona como inhibidor de elastasa de neutrófilos | |
| MX2021009584A (es) | Nuevos derivados de triterpeno como inhibidores del virus de la inmunodeficiencia humana (vih). | |
| CO2024000832A2 (es) | Inhibidores de transglutaminasas | |
| MX2021005688A (es) | Compuestos de piridina sulfonamida para el tratamiento contra afecciones relacionadas con interleucina 1 beta. |